| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Braden B | The best and worst treatments for Helicobacter pylori. | 2015 | BMJ | pmid:26290321 |
| Li BZ et al. | Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. | 2015 | BMJ | pmid:26290044 |
| Haider RB et al. | A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. | 2015 | Eur J Gastroenterol Hepatol | pmid:26287955 |
| Shallom SJ et al. | New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group. | 2015 | J. Clin. Microbiol. | pmid:26269619 |
| Zagari RM et al. | Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. | 2015 | Dig Liver Dis | pmid:26253555 |
| Sprague J et al. | Cutaneous infection with Mycobacterium kansasii in a patient with myelodysplastic syndrome and Sweet syndrome. | 2015 | Cutis | pmid:26244358 |
| Sharara AI et al. | Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238584 |
| Graham DY and Gisbert JP | Letter: clarithromycin dose for H. pylori therapy remains unresolved. | 2015 | Aliment. Pharmacol. Ther. | pmid:26238583 |
| Navarro-Jarabo JM et al. | Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. | 2015 | Digestion | pmid:26227669 |
| Ufuk A et al. | In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. | 2015 | Pharm. Res. | pmid:26224396 |
| Cohen O et al. | Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori. | 2015 | Rheumatol. Int. | pmid:26210999 |
| Fraser LA et al. | Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study. | 2015 | Ann Pharmacother | pmid:25429094 |
| Dimer F et al. | Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. | 2015 | Pharm. Res. | pmid:26113237 |
| Kasai A et al. | Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. | 2015 | J. Med. Microbiol. | pmid:25934551 |
| Chou HW et al. | Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. | 2015 | Clin. Infect. Dis. | pmid:25409476 |
| Mahmoudi A et al. | Microbiological assay for the analysis of certain macrolides in pharmaceutical dosage forms. | 2015 | Int J Pharm | pmid:26112961 |
| Flores-Gonzalez JC et al. | [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. | 2015 | Rev Neurol | pmid:26108903 |
| Jeong BH et al. | Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. | 2015 | Am. J. Respir. Crit. Care Med. | pmid:25393520 |
| Hill FJ et al. | From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. | 2015 | BMJ Case Rep | pmid:26106178 |
| Yu T et al. | Study on clarithromycin lactobionate based dual selector systems for the enantioseparation of basic drugs in capillary electrophoresis. | 2015 | J Sep Sci | pmid:26097042 |
| Trotti LM et al. | Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. | 2015 | Ann. Neurol. | pmid:26094838 |
| Tai WC et al. | Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication. | 2015 | Biomed Res Int | pmid:26090428 |
| Nguyen AT et al. | Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections. | 2015 | Cornea | pmid:26075451 |
| Hwang JJ et al. | Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. | 2015 | World J. Gastroenterol. | pmid:25945019 |
| Liou JM et al. | The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. | 2015 | PLoS ONE | pmid:25942450 |
| Ferreri AJ et al. | High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. | 2015 | Ann. Oncol. | pmid:25935794 |
| Ito A et al. | Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital. | 2015 | J. Med. Microbiol. | pmid:25934550 |
| AktaÅŸ B et al. | The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. | 2015 | Eur J Gastroenterol Hepatol | pmid:25919773 |
| Lam A et al. | Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells. | 2015 | Int Forum Allergy Rhinol | pmid:25907295 |
| Luo RF et al. | Rapid Detection of Acquired and Inducible Clarithromycin Resistance in Mycobacterium abscessus Group by a Simple Real-Time PCR Assay. | 2015 | J. Clin. Microbiol. | pmid:25903572 |
| Takahashi C et al. | Observation of antibacterial effect of biodegradable polymeric nanoparticles on Staphylococcus epidermidis biofilm using FE-SEM with an ionic liquid. | 2015 | Microscopy (Oxf) | pmid:25757698 |
| Metanat HA et al. | Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial. | 2015 | Helicobacter | pmid:25752357 |
| Essilfie AT et al. | Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. | 2015 | Thorax | pmid:25746630 |
| Bouilhat N et al. | High-level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study. | 2015 | Helicobacter | pmid:25735573 |
| Guzman Vinasco L et al. | Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man. | 2015 | BMJ Case Rep | pmid:25733094 |
| Mitsui Y et al. | Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication. | 2015 | Clin J Gastroenterol | pmid:25733031 |
| Ben Chaabane N and Al-Adhba HS | Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. | 2015 | Indian J Gastroenterol | pmid:25721770 |
| Townsell MY et al. | Pathology in practice. Canine distemper virus disease in a dog. | 2015 | J. Am. Vet. Med. Assoc. | pmid:25719842 |
| Scherübl H et al. | [What is new in treating Helicobacter pylori infection?]. | 2015 | Dtsch. Med. Wochenschr. | pmid:25704525 |
| Hur J et al. | Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 | Chem. Res. Toxicol. | pmid:25811541 |
| Aoki H et al. | Clarithromycin highly-loaded gastro-floating fine granules prepared by high-shear melt granulation can enhance the efficacy of Helicobacter pylori eradication. | 2015 | Eur J Pharm Biopharm | pmid:25703356 |
| Baysal B et al. | Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. | 2015 | Turk J Gastroenterol | pmid:25698264 |
| Blix HS et al. | Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? | 2015 | Epidemiol. Infect. | pmid:25388750 |
| Chu HS et al. | Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. | 2015 | PLoS ONE | pmid:25581038 |
| Lee HJ et al. | Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. | 2015 | World J. Gastroenterol. | pmid:25574111 |
| Brown-Elliott BA et al. | Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. | 2015 | J. Clin. Microbiol. | pmid:25568437 |
| Amiri M | Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura. | 2015 | Glob J Health Sci | pmid:26925898 |
| Haghi M et al. | Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. | 2015 | Pharm. Res. | pmid:25537341 |
| Li DQ et al. | Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. | 2015 | CMAJ | pmid:25534598 |
| Boltin D et al. | Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? | 2015 | J. Clin. Microbiol. | pmid:25428158 |
| Zhang L et al. | [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection]. | 2015 | Zhonghua Nei Ke Za Zhi | pmid:26887366 |
| Moriya S et al. | Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells. | 2015 | Int. J. Oncol. | pmid:25422130 |
| Montes M et al. | Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. | 2015 | Helicobacter | pmid:25382231 |
| Wang B et al. | Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. | 2015 | Helicobacter | pmid:25381839 |
| Yoon K et al. | Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea. | 2015 | J. Gastroenterol. Hepatol. | pmid:25363555 |
| Tongtawee T et al. | High Prevalence of Helicobacter pylori Resistance to Clarithromycin: a Hospital-Based Cross-Sectional Study in Nakhon Ratchasima Province, Northeast of Thailand. | 2015 | Asian Pac. J. Cancer Prev. | pmid:26745073 |
| Park JB et al. | Modulation of microenvironmental pH and utilization of alkalizers in crystalline solid dispersion for enhanced solubility and stability of clarithromicin. | 2015 | Arch. Pharm. Res. | pmid:25213008 |
| Anton E et al. | Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. | 2015 | Antimicrob. Agents Chemother. | pmid:26711765 |
| Bang CS et al. | Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection. | 2015 | Gut Liver | pmid:25167799 |
| Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
| Winters N et al. | Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. | 2015 | Eur. Respir. J. | pmid:26381514 |
| Baumann M et al. | Aquatic toxicity of the macrolide antibiotic clarithromycin and its metabolites. | 2015 | Chemosphere | pmid:25051235 |
| Kakked GA et al. | Pneumobilia with gastric outlet obstruction. | 2015 | BMJ Case Rep | pmid:26552878 |
| Kim SE et al. | Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. | 2015 | Korean J. Intern. Med. | pmid:26552455 |
| Bang CS and Baik GH | Time to learn from the past and prepare for the future in Helicobacter pylori eradication. | 2015 | Korean J. Intern. Med. | pmid:26552453 |
| Alimadadi M et al. | Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. | 2015 | Iran J Kidney Dis | pmid:26552348 |
| Karpiński TM et al. | Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. | 2015 | Acta Microbiol Immunol Hung | pmid:26551571 |
| John A et al. | Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection? | 2015 | Indian J Gastroenterol | pmid:26541342 |
| Mel-Hennawi D and Ahmed MR | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2015 | J Laryngol Otol | pmid:26521817 |
| Parra D et al. | In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. | 2015 | BMC Microbiol. | pmid:26518881 |
| Xing J et al. | The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans. | 2015 | Anal. Chim. Acta | pmid:26515003 |
| Demirci H et al. | Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. | 2015 | Turk J Gastroenterol | pmid:26510082 |
| Bérard A et al. | Use of macrolides during pregnancy and the risk of birth defects: a population-based study. | 2015 | Pharmacoepidemiol Drug Saf | pmid:26513406 |
| Chen KY et al. | Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. | 2015 | World J. Gastroenterol. | pmid:26420970 |
| Apiwattankul N et al. | Infections Caused by Rapidly Growing Mycobacteria spp in Children and Adolescents With Cancer. | 2015 | J Pediatric Infect Dis Soc | pmid:26407409 |
| Hwang JJ et al. | Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. | 2015 | World J. Gastroenterol. | pmid:26401089 |
| Weiss S et al. | Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. | 2015 | Antimicrob. Agents Chemother. | pmid:26392505 |
| Agrawal V et al. | A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. | 2015 | J Am Geriatr Soc | pmid:26389998 |
| Hauser G et al. | Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. | 2015 | Medicine (Baltimore) | pmid:25929897 |
| Glocker EO | The Need for Resistance Surveillance and Antimicrobial Susceptibility Testing of Helicobacter pylori. | 2015 | Digestion | pmid:26372776 |
| Bruhn DF et al. | In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. | 2015 | Sci Rep | pmid:26365087 |
| Ledwoń A et al. | Multidrug therapy of Mycobacterium avium subsp. avium infection in experimentally inoculated budgerigars (Melopsittacus undulatus). | 2015 | Avian Pathol. | pmid:26364975 |
| Picoli SU et al. | Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. | 2014 May-Jun | Rev. Inst. Med. Trop. Sao Paulo | pmid:24878996 |
| UÄŸurlu T et al. | Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. | 2014 Mar-Apr | Acta Pol Pharm | pmid:25272652 |
| Skvarc M et al. | Multi locus sequence typing (MLST) used as a tool to confirm the ability of susceptible Helicobacter pylori strains to gain resistance to clarithromycin during eradication therapy. | 2014 Jan-Feb | Hepatogastroenterology | pmid:24895826 |
| Hanson KE et al. | Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? | 2014 | J. Clin. Microbiol. | pmid:24554745 |
| Almeida N et al. | Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. | 2014 | Helicobacter | pmid:24506175 |
| Markert C et al. | Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. | 2014 | Br J Clin Pharmacol | pmid:23738582 |
| Pathak V et al. | Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. | 2014 | Ann Am Thorac Soc | pmid:24460438 |
| Wu JY et al. | Evidence-based recommendations for successful Helicobacter pylori treatment. | 2014 | Expert Rev Gastroenterol Hepatol | pmid:24410470 |
| DÃaz Cuevas Z et al. | [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. | 2014 | Med Clin (Barc) | pmid:23877097 |
| Maurer FP et al. | Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. | 2014 | J. Antimicrob. Chemother. | pmid:24500188 |
| Farley R et al. | Antibiotics for bronchiolitis in children under two years of age. | 2014 | Cochrane Database Syst Rev | pmid:25300167 |
| Hemphill A et al. | Treatment of echinococcosis: albendazole and mebendazole--what else? | 2014 | Parasite | pmid:25526545 |
| Kawai T et al. | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). | 2014 | J. Gastroenterol. Hepatol. | pmid:25521730 |
| Wang B et al. | Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. | 2014 | World J. Gastroenterol. | pmid:25356059 |
| de Boer EM et al. | [Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment]. | 2014 | Ned Tijdschr Geneeskd | pmid:25159698 |
| Lee JW et al. | A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. | 2014 | Scand. J. Gastroenterol. | pmid:24988873 |
| Adebisi AO and Conway BR | Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. | 2014 | Int J Pharm | pmid:24792977 |
| Bolhuis MS et al. | In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. | 2014 | Eur. Respir. J. | pmid:24791826 |